SK Biopharmaceuticals succeeded in recording an operating profit for the third consecutive quarter.

SK Biopharmaceuticals, which had been in the red for a long time until Q3 last year, has been in the black since Q4 last year.

This is due to the strong performance of its epilepsy drug Xcopri (cenobamate) in the U.S. market. Xcopir’s sales in the U.S. exceeded KRW 100 billion in Q2 this year.

Successfully achieved a profit for 3 consecutive quarters since Q4 last year

On the 8th, SK Biopharmaceuticals posted an operating profit of KRW 26 billion in Q2 last year according to the Financial Supervisory Service. SK Biopharmaceuticals, which posted an oper